Reproducibility of histologic prognostic parameters for mantle cell lymphoma: cytology, Ki67, p53 and SOX11

[1]  L. Quintanilla‐Martinez,et al.  Highly sensitive and specific in situ hybridization assay for quantification of SOX11 mRNA in mantle cell lymphoma reveals association of TP53 mutations with negative and low SOX11 expression , 2019, Haematologica.

[2]  W. Klapper,et al.  Blastoid and pleomorphic mantle cell lymphoma: still a diagnostic and therapeutic challenge! , 2018, Blood.

[3]  A. Rosenwald,et al.  Validation of the MCL35 gene expression proliferation assay in randomized trials of the European Mantle Cell Lymphoma Network , 2018, British journal of haematology.

[4]  R. Spang,et al.  Round-robin test for the cell-of-origin classification of diffuse large B-cell lymphoma—a feasibility study using full slide staining , 2018, Virchows Archiv.

[5]  G. Klöppel,et al.  Ki67 labeling index: assessment and prognostic role in gastroenteropancreatic neuroendocrine neoplasms , 2018, Virchows Archiv.

[6]  A. Rosenwald,et al.  Expression of TP53 is associated with the outcome of MCL independent of MIPI and Ki-67 in trials of the European MCL Network. , 2018, Blood.

[7]  B. Győrffy,et al.  Comparison of 5 Ki-67 antibodies regarding reproducibility and capacity to predict prognosis in breast cancer: does the antibody matter? , 2017, Human pathology.

[8]  M. Dreyling,et al.  Mantle cell lymphoma - Current standards of care and future directions. , 2017, Cancer treatment reviews.

[9]  M. Ladetto,et al.  Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  J. Rüschoff,et al.  Quality assurance trials for Ki67 assessment in pathology , 2017, Virchows Archiv.

[11]  L. Staudt,et al.  New Molecular Assay for the Proliferation Signature in Mantle Cell Lymphoma Applicable to Formalin-Fixed Paraffin-Embedded Biopsies. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  A. Rosenwald,et al.  Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Florian Länger,et al.  The region-of-interest size impacts on Ki67 quantification by computer-assisted image analysis in breast cancer. , 2015, Human pathology.

[14]  W. Klapper,et al.  New Paradigms in Mantle Cell Lymphoma: Is It Time to Risk-Stratify Treatment Based on the Proliferative Signature? , 2014, Clinical Cancer Research.

[15]  M. Ghielmini,et al.  Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  J. Delabie,et al.  SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma – a Nordic Lymphoma Group study , 2014, British journal of haematology.

[17]  E. Campo,et al.  Assessment of SOX11 Expression in Routine Lymphoma Tissue Sections: Characterization of New Monoclonal Antibodies for Diagnosis of Mantle Cell Lymphoma , 2014, The American journal of surgical pathology.

[18]  John M S Bartlett,et al.  An international Ki67 reproducibility study. , 2013, Journal of the National Cancer Institute.

[19]  B. Sander,et al.  Prognostic role of SOX11 in a population-based cohort of mantle cell lymphoma. , 2012, Blood.

[20]  Jeroen van der Laak,et al.  Ki-67 as a prognostic marker in mantle cell lymphoma—consensus guidelines of the pathology panel of the European MCL Network , 2009, Journal of hematopathology.

[21]  A Rosenwald,et al.  Retracted: Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications (a study from the Lunenburg Lymphoma Biomarker Consortium) , 2007, Journal of Clinical Pathology.

[22]  W. Klapper,et al.  Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network , 2005, British journal of haematology.

[23]  Thomas Rüdiger,et al.  Inter‐laboratory and inter‐observer reproducibility of immunohistochemical assessment of the Ki‐67 labelling index in a large multi‐centre trial , 2002, The Journal of pathology.

[24]  E. Giné,et al.  A new molecular assay and genomic complexity predict outcome in conventional and leukemic non-nodal mantle cell lymphoma , 2018 .

[25]  E. Hoster,et al.  European mantle cell lymphoma network , 2008 .